Uropathogenic Escherichia coli FimH adhesin (FimH) (FimH)

Uropathogenic Escherichia coli FimH adhesin is a 30-kDa protein located at the distal tip of type 1 fimbriae, which are hair-like appendages on the surface of many Gram-negative bacteria (UniProt P08191; NIH.gov). It functions as a mannose-specific lectin, mediating the critical first step of bacterial infection by binding to mannosylated glycoproteins on host cell surfaces, such as uroplakins in the bladder and CEACAM6 in the intestinal epithelium (NIH.gov; BenchChem.com). This adhesion allows uropathogenic E. coli (UPEC) and adherent-invasive E. coli (AIEC) to resist mechanical clearance by urine flow, colonize tissues, and invade host cells, leading to urinary tract infections (UTIs) and contributing to the pathogenesis of Crohn's disease (NIH.gov; Enterome.com). Beyond its role in adhesion, FimH can act as a ligand for Toll-like receptor 4 (TLR4), triggering innate immune responses that may exacerbate inflammatory conditions like colitis (Frontiersin.org; PLOS.org). Recent research also suggests that FimH-mediated adhesion is necessary for the delivery of the genotoxin colibactin, thereby promoting DNA damage and colorectal cancer development (Nature.com; ResearchGate.net). Therapeutic strategies targeting FimH focus on small-molecule mannoside antagonists, such as sibofimloc (TAK-018) and GSK3882347, which competitively inhibit the mannose-binding site (Bioworld.com; Enterome.com). These anti-adhesive drugs aim to disarm the bacteria and prevent colonization without the selective pressure for resistance associated with traditional antibiotics, offering a microbiome-sparing approach to treating mucosal infections (Patsnap.com; Enterome.com).

Other names

Type 1 fimbrin D-mannose specific adhesinType 1 pilus adhesinFimH proteinMannose-binding lectin domain of FimH

Competitive inhibition of the mannose-binding lectin domain to prevent bacterial adhesion to host cells.